Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, September 25, 2025 –Santhera Pharmaceuticals (SIX: SANN) today provides the following update regarding its convertible bond announced on 23 September 2025: Details:The conversion price has been set at CHF 13.5446, representing a 10% premium to the volume-weighted average price (VWAP) of Santhera’s shares on 23 September 2025. The coupon is 7%, reflecting a reduction compared with the previous bond.The aggregate...
Nasdaq GlobeNewswire
25/09/2025
Press release: Sequana Medical announces H1 2025 results and provides business…
Sequana Medical announces H1 2025 results and provides business update alfapump® US commercialisation underway; Strengthened US reimbursement with CMS approval of NTAP “top-up” reimbursement; On track for at least 70 US commercial alfapump implants during “Soft Launch” – “Full Launch” on track for Q2 2026Debt reduction of EUR 2 million through partial conversion of Kreos loan and 2025 convertible loanTotal liquidity position of EUR 7.3 million as per 30 June 2025 ...
Nasdaq GlobeNewswire
25/09/2025
Fagron announces the acquisition of UCP in North America and FDA inspection…
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 25 September 2025 – 7:00 AM CET Fagron announces the acquisition of UCP in North America and FDA inspection updateFagron, the leading global player in pharmaceutical compounding, is pleased to announce a strategic acquisition that will significantly reinforce its presence in North America. The company has signed the acquisition of University Compounding Pharmacy (UCP), a 503A pharmaceutical...
Nasdaq GlobeNewswire
25/09/2025
H1 25 Results Confirm the Relevance of Roquette’s Strategy
H1 25 Results Confirm the Relevance of Roquette’s StrategyRoquette outperforms its key markets, delivering solid H1 results in current complex market conditions.Successful completion of the acquisition of IFF Pharma Solutions 1 and implementation of a new organization with two complementary Business Groups 2.+4% turnover growth to €2,371 million (-3% Like-For-Like basis, LFL 3 ) and +18% EBITDA increase to €294 million (-1% LFL), supported by a favorable mix effect...
Nasdaq GlobeNewswire
25/09/2025
Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at…
Moderate-to-Severe Acute Pain Market Summary Moderate-to-Severe Acute Pain Market Summary Discover which therapies are expected to grab the major moderate-to-severe acute pain treatment market share @Moderate-to-Severe Acute Pain Market Report Key Factors Driving the Moderate-to-Severe Acute Pain Market Growing Moderate to Severe Acute Pain Incidence The total number of incident cases of moderate-to-severe acute pain in the 7MM were around180 millionin 2024...
PR Newswire
24/09/2025
uniQure Announces $200 Million Proposed Public Offering
Leerink Partners, Stifel, Van Lanschot Kempen, and Guggenheim Securities are acting as bookrunning managers for the proposed offering.The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the...
Nasdaq GlobeNewswire
24/09/2025
Inventiva to Host Analyst and Investor Event on October 8, 2025
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient representative will highlight key trends shaping the MASH treatment landscapeDaix (France), New York City (New York, United States), September 24, 2025 –Inventiva(Euronext Paris and NASDAQ:IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Nasdaq GlobeNewswire
24/09/2025
CROSSJECT presents its financial results and key highlights for the first half…
Press releaseCROSSJECT presents its financial results and key highlights for the first half of 2025Cash position: €6.3 million, compared to €7.0 million as of December 31 2024, demonstrating the Company's excellent control of its resources. Stable R&D investments and a €3.1 million increase in R&D reimbursements from BARDA1 for the first half of 2024, to €6.5 million, in line with the focus on regulatory development and batch manufacturing related to the registration...
Nasdaq GlobeNewswire
24/09/2025
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS…
Robert Montgomery, MD, PhD, New York University Langone Health, said: "There have been few major breakthroughs in desensitization strategies in kidney transplantation for the last 30 years. The unmet need remains high for kidney transplant patients who are considered highly sensitized, with many remaining on the wait list with little to no hope of receiving a suitable match for transplantation. The result from the US ConfIdeS trial are highly encouraging and demonstrate the significant…
PR Newswire
24/09/2025
Groupe Bastide completes the sale of Baywater Healthcare to Sapio Group
Caissargues, September 24, 2025 In line with the timetable set out in its 30 June 2025 communication announcing the agreement to sell Baywater Healthcare, a leading player in the UK respiratory care market, to Sapio Group, Groupe Bastide today announced that it has completed the sale of its UK subsidiary…
Actusnews Wire
24/09/2025
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on…
H1 2025 results Activity and profitabilityH1 revenue: €387.8 million, down 5.4% at CER 1and on a like-for-like basis 2, mainly due to the decline in activity in FranceRestated EBITDA margin 3came out at 12.9%, compared with 15.4% a year earlier2025 financial targetsRevenue: slight decrease of approximately 1% at CER and on a like-for-like basisRestated EBITDA margin: between 12% and 13% of revenueFree cash flow: slightly negativeVillepinte, September 24, 2025,...
Nasdaq GlobeNewswire
24/09/2025
EUROBIO SCIENTIFIC: RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025 Revenue up 10% to €80.7 millionProprietary products account for 36% of revenue42% of revenue generated outside France2025 results impacted by the transfer of EndoPredict®/Prolaris® production to FranceFree cash flow after investment of €4.4 millionNet debt of €-2.2 million including EB Development current account Paris, September 24, 2025 - 5:40 p.m. - Eurobio Scientific ( FR0013240934, ALERS, eligible for...
Nasdaq GlobeNewswire
24/09/2025
Mobile Gamma Cameras Market Surges to USD 800 Million by 2033, Propelled by 7.3%…
Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=840016 Download PDF Brochure:https://www.verifiedmarketreports.com/download-sample/?rid=840016 Browse in-depth TOC on Mobile Gamma Cameras Market 202 - Pages 126 – Tables 37 – Figures Scope of The Mobile Gamma Cameras Market Report Basda segment scope Global Mobile Gamma Cameras Market Overview Mobile Gamma Cameras Market: Trends and Opportunities ...
PR Newswire
24/09/2025
Mintel Most Innovative 2026: Recognizing the CPG Products Redefining the Future
"CPG innovation has never moved faster or felt more pressured. Consumers of all ages, especially Gen Alpha, Gen Z and Millennials, are eager to experiment and try new things, and they expect brands not just to keep up, but to stay a step ahead. Despite this urgency, true innovation is at an all-time low, with too many launches relying on safe, incremental updates," said Julie Lizer, President of Global Research and Insights at Mintel. "The tension between the pace of consumer…
PR Newswire
24/09/2025
In Vitro Diagnostics (IVD) Quality Control Market Poised for Strong Growth Amid…
The IVD Quality Control Market is witnessing significant growth as healthcare providers prioritize accurate and reliable diagnostic testing. The IVD Quality Control Market is witnessing significant growth as healthcare providers prioritize accurate and reliable diagnostic testing. For a detailed analysis of industry trends and growth drivers, explore the full In Vitro Diagnostics (IVD) Quality Control Market. Browse in-depth TOC 202 - Pages 126 - Tables 37 -...
PR Newswire
24/09/2025
Digital Migraine Treatment Devices Market to Reach USD 298.71 Million by 2030…
Download Exclusive Sample Report: https://www.datamintelligence.com/download-sample/digital-migraine-treatment-device-market Download Exclusive Sample Report:https://www.datamintelligence.com/download-sample/digital-migraine-treatment-device-market Browse in-depth TOC on "Digital Migraine Treatment Device Market" 70 – Tables 66 – Figures 195 – Pages Market Segmentation Analysis By Type By Application Hospitals remained the leading end-user in 2024, generating...
PR Newswire
24/09/2025
Financière de Tubize strengthens its expertise in the biopharma field by…
Since the appointment of Bruno Holthof as Chairman of the Board of Directors of the company in April 2025, the company's board has continued to strengthen its expertise in the biopharma field. This aims to best support UCB and contribute to the development of a sustainable biopharma ecosystem in Belgium, the United Kingdom, and other relevant geographical areas for UCB.The Extraordinary General Meeting held yesterday confirmed the appointment of two new directors, Iris Löw-Friedrich and...
Nasdaq GlobeNewswire
24/09/2025
Leo Cancer Care Raises $40 Million to Advance Upright Radiotherapy Innovations…
This substantial investment will accelerate commercialization of Leo Cancer Care's next-generation upright radiotherapy system, designed to enhance patient outcomes and broaden access to advanced cancer treatment. As part of the funding round, Catalio's Dr. Nicholas von Guionneau, joins Leo Cancer Care's board as an Observer. This substantial investment will accelerate commercialization of Leo Cancer Care's next-generation upright radiotherapy system, designed to enhance patient outcomes and...
PR Newswire
24/09/2025
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab…
TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025, in Barcelona, Spain. The ECTRIMS Congress is the world’s largest annual...
Nasdaq GlobeNewswire
24/09/2025
EGI Launches Next-Generation HD-EEG Platform to Advance Understanding of Brain…
Innovator of HD-EEG releases world’s most advanced EEG brain monitoring technology for neuroscience research Electroencephalography (EEG) enables researchers and clinicians to noninvasively capture the brain’s electrical activity for insights into health, disease, and patient care. EGI innovated the gold standard in HD-EEG technology, cited in more than 4,000 research papers, including pivotal studies in depression, sleep, autism, Alzheimer’s disease and pharmaceutical development...
Nasdaq GlobeNewswire
24/09/2025
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in…
TOKYO and CAMBRIDGE, Mass., Sept.24, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI ® ” (brand name, generic name: lecanemab) for mild cognitive...
Nasdaq GlobeNewswire
24/09/2025
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an…
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~~ Additional $100 million available subject to regulatory and financial milestones ~~ Additional $25 million available subject to Hercules’ approval ~~ Transaction provides financial flexibility and improves cost of capital ~ LEXINGTON, Mass. and AMSTERDAM, Sept.24, 2025(GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies...
Nasdaq GlobeNewswire
24/09/2025
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of…
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~~ High-dose AMT-130 also demonstrated statistically significant slowing of disease progression as measured by TFC, a key secondary endpoint, and favorable trends across additional clinical measures ~~ Mean cerebrospinal fluid NfL levels were below baseline at 36 months ~~...
Nasdaq GlobeNewswire
24/09/2025
The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global…
In the Asia Pacific and Middle East region, two in three individuals (66%) skip routine heart tests, while nearly half (45%) do not recognize genetics as a risk factor of heart disease, according to the results of a recent survey commissioned by Novartis. Awareness of Lp(a) is even lower, with just 22% of respondent reporting they had heard of a test for the biomarker, while only 7% had taken it.7 In theAsia PacificandMiddle Eastregion, two in three individuals (66%) skip routine heart...
PR Newswire
24/09/2025
Altri Comunicati
